Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 11:24 PM
Ignite Modification Date:
2025-12-25 @ 9:10 PM
NCT ID:
NCT00095056
Group ID:
EG001
Title:
Placebo
Description:
The Placebo group includes data from patients randomized to receive treatment with either one (1) tablet of placebo matching sitagliptin 25 mg (blinded) \[patients with CrCl \<30 mL/min or dialysis\] or two (2) tablets of placebo matching sitagliptin 25 mg (blinded) \[patients with CrCl 30 to \<50mL/min\] alone or in combination with baseline insulin therapy. During Phase B, patients in the Placebo group (with the exception of patients on baseline insulin therapy and patients who received glycemic rescue medication in Phase A) were given glipizide (blinded). During Phase B, patients on baseline insulin could have their insulin uptitrated, and patients who received glycemic rescue medication in Phase A continued on open-label rescue medication.
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
10
Serious Number At Risk:
26
Other Number Affected:
20
Other Number At Risk:
26
Study:
NCT00095056
Results Section:
NCT00095056
Adverse Events Module:
NCT00095056